The European Medicines Agency Road Map to 2015: Independence should be the priority (Joint Contribution to EMA Consultation, April 2010)
Joint contribution to the public consultation
Brussels, 30 April 2010
HAI Europe, ISDB and Medicines in Europe Forum answer to EMA’s public consultation on its road map to 2015.
Pharmacovigilance in Europe: the European Commission’s proposals endanger the population
A series of public health disasters (from thalidomide in the 1960s to rofecoxib (Vioxx°) at the beginning of this century) have served to remind us of the crucial nature of pharmacovigilance. To this end, the European Commission’s proposed legislative changes represent a serious regression in the protection of European citizens.
Health Action International (HAI) Europe, International Society of Drug Bulletins (ISDB) and Medicine in Europe Forum (MiEF) find that “EMEA’s draft transparency policy” fails to restore citizens’ trust in its decision-making.